Perceives Failure
"If I'm put on insulin, I must be doing something wrong."
- Perceives Failure

About 40% of patients with diabetes were not at A1C goal of <7%1,a

You may want to have the insulin talk sooner

Insulin is a chance for successful glycemic control, not a punishment for failure.

About 40% of patients with diabetes were not at A1C goal of <7%1,a



Percent of type 2 patients with A1C <7%, NHANES data, 1988-2004

Insulin does not mean a personal defeat in the battle against diabetes and does not need to be considered as a last resort. You can help patients focus on turning a negative mindset into positive action for managing their disease.2 If your patients are not adequately controlled and are having trouble reaching their A1C goals, insulin is an effective option to help lower blood glucose.3

  • Patients should not see insulin as a sign of failure. Learn More
  • Education may help patients better manage their diabetes. Learn More
  • Turn the negative mindset into a positive action for managing their diabetes.  Learn More
Next >

Important Safety Information for Lantus®

Contraindications

Lantus® is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus® with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus® via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus®, and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus® dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus® are injection site reaction, lipodystrophy, pruritus, and rash.

Important Safety Information for Lantus® SoloSTAR®

Lantus® SoloSTAR® is a disposable prefilled insulin pen. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose.

Indications and Usage for Lantus®

Lantus® is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus® should be administered once a day at the same time every day.

Important Limitations of Use: Lantus® is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Please click here for full prescribing information

a National Health and Nutrition Examination Survey (NHANES), 2003-2004.

References: 1. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Diabetes Care. 2008;31(1):81-86.
2. Polonsky WH, Jackson RA. Clin Diabetes. 2004;22(3):147-150.
3. Nathan DM et al. Diabetes Care. 2009;32(1):193-203.